Statement of Investor Complaint ,Regulation 13(3) of SEBI LODR ,2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences Ltd has submitted its quarterly and annual statement of investor complaints to BSE as required under SEBI LODR Regulation 13(3). The report covers the period from January 2025 to March 2025 and the full financial year ended 31 March 2025. Across all categories — SEBI (SCORE portal), BSE/NSE, Shareholders/Investors, and the ODR Smart Portal — the opening balance, complaints received, resolved, and pending were all reported as NIL. The certificate was issued by the company's Registrar, Beetal Financial & Computer Services Pvt. Ltd., confirming zero investor grievances during the period.
A NIL complaint report signals healthy shareholder servicing and no unresolved investor issues, which is a neutral-to-positive compliance indicator. For shareholders, this means there were no pending grievances against the company during the quarter or full financial year.